Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gluco-oligosaccharides (GluOS) are short-chain carbohydrate molecules composed of glucose units linked by various glycosidic bonds, such as alpha-1,4, alpha-1,6, or beta-1,3 linkages [1][2]. These molecules are primarily recognized for their role as prebiotics, which are non-digestible food ingredients that selectively stimulate the growth and activity of beneficial gut bacteria, particularly Bifidobacterium and Lactobacillus species [3][4]. By undergoing fermentation in the large intestine, gluco-oligosaccharides contribute to the production of short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate, which are essential for maintaining colonic health and modulating systemic inflammatory responses [2][5]. In clinical pharmacology, gluco-oligosaccharides are generally classified as active agents or substrates rather than traditional therapeutic targets like receptors or enzymes [6]. However, their metabolic processing is a key focus in treating type 2 diabetes, where alpha-glucosidase inhibitors are used to prevent their hydrolysis into glucose, thereby managing postprandial hyperglycemia [7][8]. Furthermore, specific gluco-oligosaccharide structures, such as beta-linked variants, can serve as ligands for innate immune receptors like Dectin-1 or as antigenic biomarkers (e.g., laminaribioside) for the diagnosis and stratification of inflammatory bowel diseases [9][10].
Gluco-oligosaccharides primarily act as prebiotic substrates that undergo selective fermentation by beneficial gut bacteria, leading to the production of metabolites like SCFAs. In the context of drug interaction, they are the substrates for alpha-glucosidase enzymes; drugs like Acarbose competitively inhibit these enzymes to prevent the breakdown of gluco-oligosaccharides into glucose, thereby slowing carbohydrate absorption.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gluco-oligosaccharide (GluOS).